Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 36Colorectal Neoplasms 17Small Cell Lung Carcinoma 8Neoplasms 8Stomach Neoplasms 7Neoplasm Metastasis 5Sarcoma, Ewing 4Rhabdomyosarcoma 4Recurrence 4Osteosarcoma 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Ovarian Neoplasms 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Solid Tumor 2Neuroblastoma 2Nasopharyngeal Carcinoma 2Metastatic Pancreatic Adenocarcinoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Wilms Tumor 1Weight Loss 1Somatostatinoma 1Solid Tumor Cancer 1Small Cell Lung Cancer Extensive Stage 1

Interventions

lutetium Lu 177 dotatate 6lanreotide 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3copper dotatate CU-64 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Magnetic Resonance Spectroscopy 2Lutetium-177 2Lutetium 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastro-enteropancreatic neuroendocrine tumor × irinotecan sucrosofate × Clear all
NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡